Research

Evidence Base

What the Candidates Don’t Get About Drug Prices

March 19, 2016

Featured Experts: Dana Goldman, PhD

Evidence Base

What the Candidates Don’t Get About Drug Prices

March 18, 2016

Featured Experts: Dana Goldman, PhD

Journal Article

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand

February 28, 2016

Journal Article

Comparative Effectiveness of Panitumumab (P) and Cetuximab (C) in Metastatic Colorectal Cancer (mCRC) with Wild-Type KRAS (WTKRAS)

February 1, 2016

Journal Article

Comparative Effectiveness of FOLFIRINOX (FOL) versus Gemcitabine and Nab-Paclitaxel (GNP) for the First-Line Treatment of Metastatic Pancreatic Cancer

February 1, 2016

Journal Article

Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010

January 31, 2016

Journal Article

The Economic Promise of Delayed Aging

December 18, 2015

Featured Experts: Dana Goldman, PhD

Journal Article

A System to Build Distributed Multivariate Models and Manage Disparate Data Sharing Policies: Implementation in the Scalable National Network for Effectiveness Research

November 30, 2015

Journal Article

Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in US and Canadian Clinical Practice

November 30, 2015

Journal Article

NBER Working Paper: Prescription Drug Advertising and Drug Utilization – The Role of Medicare Part D

November 30, 2015

Featured Experts: Darius Lakdawalla, PhD, Neeraj Sood, PhD

Perspective

Drop Medicaid ‘Best Price’ Rule Drug Rules in Favor of Value-Based Strategies

November 19, 2015

Featured Experts: Dana Goldman, PhD

Evidence Base

For Vulnerable Populations, the Medicare Part D Doughnut Hole Disrupts Medication Adherence

November 12, 2015

Journal Article

Understanding Patient Preferences and Willingness to Pay for Hemophilia Therapies

November 11, 2015

Journal Article

Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern

October 31, 2015

Featured Experts: Karen Van Nuys, PhD, Dana Goldman, PhD

Journal Article

Promise of Precision Medicine

October 27, 2015

News

Treating 5 percent of hepatitis C patients with new drugs would reduce cost and infections, study shows

October 5, 2015

Evidence Base

A New Line of Specialty Drugs: PCSK9 Inhibitors (Part 2)

September 28, 2015

News

What’s a Fair Price? The Debate Over Value & Cost of Specialty Drugs (Part 1)

September 24, 2015

Featured Experts: Darius Lakdawalla, PhD

Perspective

Moving Beyond Price-Per-Dose In The Pharmaceutical Industry

September 15, 2015

Featured Experts: Dana Goldman, PhD, Darius Lakdawalla, PhD

News

Patients Would Give Up Over 5 Years of Life for Easier Treatments, Study Finds

September 3, 2015

Featured Experts: Dana Goldman, PhD, John Romley, PhD